ALT Q4 2020 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+301.7% YoY

Gross Profit

-$13M-548.8% margin

Operating Income

-$11M-464.8% margin

Net Income

-$11M-459.3% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-21.3%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$14M

Stock-Based Comp.

$710,486

Balance Sheet

Total Assets

$245M

Total Liabilities

$19M

Stockholders' Equity

$226M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$575,801	+301.7%
Gross Profit	-$13M	-$2M	-694.7%
Operating Income	-$11M	-$4M	-149.3%
Net Income	-$11M	-$4M	-159.3%